Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem...

Related Keywords

United States ,United Kingdom ,Houston ,Texas ,Chicago ,Illinois ,London ,City Of ,American ,Olivia Manser ,Elias Jabbour ,Susana Noonan ,Julia Wilson ,Department Of Leukemia ,Division Of Cancer Medicine ,Sa Noonan Communications ,Md Anderson Cancer Center ,American Society Of Clinical Oncology ,Exchange Commission ,Nasdaq ,Saturday June ,B Cell Acute Lymphoblastic Leukemia ,Clinical Oncology ,Annual Meeting ,Christian Itin ,Chief Executive Officer ,Stem Cell Transplant ,Oral Abstract Session ,Hematologic Malignancies ,Myelodysplastic Syndromes ,Cancer Medicine ,Cancer Center ,Autolus Therapeutics ,Private Securities Litigation Reform Act ,Autolu Annual Report ,